ClinicalTrials.Veeva

Menu

Evaluation of HIV-1 Recent Infection Testing in Rwanda

Columbia University logo

Columbia University

Status

Completed

Conditions

HIV Infections

Treatments

Other: Return of recent classification
Other: Return of long-term classification

Study type

Observational

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT05063487
AAAT5637
GG014256-18 (Other Grant/Funding Number)

Details and patient eligibility

About

The study is a longitudinal, observational cohort study of people who are newly-diagnosed with HIV who consent to recency testing and participate in index testing services, and their disclosed contacts.

The study will evaluate the impact of recency testing on HIV positive yield of index testing among the contacts of newly diagnosed people living with HIV and the incidence of adverse events or social harm as a result of returning recency results among newly diagnosed people living with HIV.

Full description

The rapid test for recent HIV infection (RTRI) assay can distinguish between people who are recently-infected and those who are long-term HIV cases. This may help guide efforts to identify ongoing HIV transmission and direct prevention or treatment efforts. But, more research is needed on the impact of RTRI on the number of HIV+ individuals that can be identified through testing. Furthermore, not much is known about the impact that returning RTRI results may have on the occurrence of intimate partner violence.

A primary objective of this study is to compare the HIV testing yield among contacts of people newly diagnosed with HIV by recency testing result. The investigators will abstract routinely collected data from participant medical records and registers. In addition, a second primary objective of this study is to assess the incidence of intimate partner violence associated with the return of recency testing results among those classified as testing recent versus long-term. Index study participants newly diagnosed with HIV will be interviewed at the initial enrollment visit following HIV diagnosis and during follow-up visits at 1, 2, and 6-months using a health-related quality of life instrument and intimate partner violence questionnaire. Participants will be recruited from 60 high-volume facilities across all provinces in Rwanda during the evaluation period.

Enrollment

1,588 patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged ≥15 years
  • Be newly diagnosed with HIV
  • Ability to speak and understand English or Kinyarwanda
  • Consented to be part of both case-based surveillance (CBS) (which includes PNS) and recency surveillance under the separate, approved CBS protocol.
  • Give voluntary written informed consent for data collection via semi-structured interview and survey instruments
  • Give voluntary written informed consent for use of routinely collected data
  • Be female if they are received at the facility at the same time as their partner (for intimate partner violence objective only).

Exclusion criteria

  • Opt out or do not consent, or are unable to consent to participate in semi-structured interviews and completion of survey instruments
  • Have a history of testing HIV positive (i.e., not newly diagnosed with HIV)
  • Report antiretroviral drug (ARV) use for HIV management at any point during the HIV testing service (HTS) visit

Trial design

1,588 participants in 2 patient groups

Recent HIV Infection
Description:
Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test recent on the rapid test for recent infection (RTRI).
Treatment:
Other: Return of recent classification
Long-Term HIV Infection
Description:
Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test long-term on the rapid test for recent infection (RTRI).
Treatment:
Other: Return of long-term classification

Trial contacts and locations

1

Loading...

Central trial contact

Suzue Saito, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems